Physiologic FDG Uptake & Benign Mimics

Quick Answer

FDG is a glucose analogue, so it accumulates wherever glucose metabolism is high — which includes many normal and benign tissues, not just tumour. The most common false positives come from a short, learnable list: brown adipose tissue, skeletal muscle, bowel, thymus, reactive marrow, inflammation/infection, and physiologic organs (brain, myocardium, urinary tract). Recognising these by their symmetry, distribution, shape, and clinical context — and using patient preparation to suppress them — prevents most overcalls.

Distribution, symmetry, and context

Three features separate physiologic/benign uptake from malignancy: symmetry (physiologic uptake is usually bilateral and symmetric; tumour is typically focal and asymmetric), anatomic conformity (benign uptake follows the shape of a muscle, fat depot, or bowel loop rather than forming a mass), and clinical/temporal context (recent exertion, cold exposure, injection, G-CSF, surgery, or infection). When uptake fits a normal structure and a plausible physiologic story, it is usually benign — but a focal, mass-like, or clinically unexpected focus deserves scrutiny regardless.

The common culprits

Brown adipose tissue (BAT). Symmetric FDG in the supraclavicular, cervical, paraspinal, mediastinal, and perirenal fat depots, more in cold, lean, young, and female patients. It follows fat (not nodes) on CT and is bilateral/symmetric. Prevention: a warm environment before and during uptake, avoiding cold exposure; some centres use additional measures. The trap is calling symmetric supraclavicular BAT nodal disease.

Skeletal muscle. Diffuse, symmetric uptake along muscle groups from recent exercise, tension, or insulin administration (insulin drives FDG into muscle — never give insulin just before FDG in a non-emergent setting). Vocal-cord uptake from talking, and diaphragmatic/paraspinal uptake from exertion, follow muscle shape.

Bowel. Variable luminal and wall uptake, often segmental, from smooth muscle, lymphoid tissue, microbiota, and metformin (which markedly increases diffuse bowel FDG). Focal fixed bowel uptake still warrants correlation (polyp/neoplasm), but diffuse bowel activity is usually physiologic or drug-related.

Thymus. In children and young adults, and after chemotherapy, the thymus shows an inverted-V ("arrowhead") of anterior mediastinal uptake — thymic rebound/hyperplasia — which mimics residual lymphoma. Its characteristic shape, symmetry, and post-treatment timing distinguish it; it typically has modest, homogeneous uptake.

Bone marrow and spleen. Diffuse, symmetric marrow and splenic uptake follows anaemia, recent chemotherapy, and especially G-CSF (colony-stimulating factor) — a classic cause of intense, diffuse marrow FDG that mimics diffuse marrow disease. Knowing the treatment history (G-CSF within roughly the preceding weeks) is essential; timing the scan away from recent G-CSF reduces it.

Inflammation and infection. FDG is avid in active inflammation and infection — post-surgical sites, radiation change, granulomatous disease (sarcoidosis, TB), and infection — a major source of false positives in oncologic staging, and simultaneously the basis of dedicated infection/inflammation imaging.

Physiologic organs. Brain (high), myocardium (diet-dependent — suppressed by high-fat/low-carbohydrate or fasting prep for cardiac inflammation studies), liver/spleen (reference regions), kidneys/ureters/bladder (excreted tracer — a common source of pelvic confusion and a reason for hydration/delayed views).

Preparation reduces the problem

Much physiologic uptake is preventable with preparation: adequate fasting and glucose control, a warm environment to suppress brown fat, avoiding exercise and insulin before injection, timing scans away from G-CSF and recent surgery, and using a high-fat/no-carbohydrate or prolonged-fast protocol when myocardial suppression is needed (cardiac sarcoid/infection). Good prep is cheaper and more reliable than trying to reason away avoidable artifacts.

Self-Check

Key References

• SNMMI/EANM FDG-PET/CT oncology procedure guidelines, including patient preparation and physiologic-uptake suppression.
• Reviews and normal-variant atlases of physiologic and benign FDG uptake (brown fat, muscle, bowel, thymic rebound, G-CSF marrow, inflammation).